Abstract
Fresh operative cells from 27 renal cell carcinomas (RCC) were culturedin vitro for the determination ofin vitro drug sensitivity. Two samples were not culturable. Incubation was carried out in triplicate in the presence and absence of various concentrations of chemotherapeutic agents. Sensitivity of the tumour cells to interferon-alpha (IFN-alpha), cisplatin (CDDP), mitomycin C (MMC), vinblastine (VBL), doxorubicin (DOX), etoposide (ETOP), bleomycin (BLM), vincristine (VCR) were tested by a colorimetric assay using MTT. A preexposure viability over 75% was essential forin vitro drug sensitivity assay (IVDSA). Sensitivity was determined by a more than 50±2 SD% reduction from the control absorbance. All eight drugs in their low concentrations exhibited cell proliferation inhibition in 0–12% of RCCs. On the other hand, IFN-alpha in its higher concentration (60 IU/ml) was effective in 88% of RCCs. After IFN, CDDP was found to be the second most effective drug in its higher concentration (36% efficacy). The results indicate that IFN appears to be the most effectivein vitro agent in our 25 RCCs and the clinical trials either as a monotherapy or multiple combinations of various agents should include IFNs for the treatment of RCC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Silverberg, E., Lubera, J.: Cancer statistics.CA, 37, 2 (1987).
Pontes, J. E.: Adjunctive treatment of renal cell carcinoma.Int. Adv. Surg. Oncol., 6, 309 (1983).
Vugrin, D.: Systemic therapy of metastatic renal cell carcinoma.Semin. Nephrol., 7, 152 (1987).
deKernion, J. B., Belldegrun, A.: Renal tumors. In: Walsh, P. C., Retik, A. B., Stamey, T. A., Vaughan, E. D. (eds.) Campbell's Urology. Saunders, Philadelphia 1992.
Rizzo, M., Bartoletti, R., Selli, C., Sicignano, A., Crisuolo, D.: Interferon alpha-2a vinblastine in the treatment of metastatic renal carcinoma.Eur. Urol. 16, 271 (1989).
Muss, H. B.: The role of biological response modifiers in metastatic renal cell carcinoma.Semin. Oncol., 15, 30 (1988).
Leone, L. A., Meitner, P. A., Thomas, M. J., Grace, W. R., Gajewski, W. H., Fingert, H. J., Rotman, B.: Predictive value of the fluorescent cytoprint assay (FCA): A retrospective correlation study of in vitro chemosensitivity and individual responses to chemotherapy.Cancer Invest., 9, 491 (1991).
Homma, Y., Aso, Y.: Effect of alpha-interferon alone and combined with other antineoplastic agents on renal cell carcinoma determined by the tetrazolium microculture assay.Eur. Urol., 25, 164 (1994).
Buzald, A. C., Todd, M. B.: Therapeutic options in renal cell carcinoma.Semin. Oncol., 16, 12 (1989).
Torti, F. M.: Treatment of metastatic renal cell carcinoma. In: Torti, F. M. (ed.) Urologic Cancer: Chemotherapeutic Principles and Management. Springer Berlin-Heidelberg-New York 1983.
Hrushesky, W. J., Murphy, G. P.: Current status of the therapy of advanced renal carcinoma.J. Surg. Oncol. 9, 277 (1977).
Walder, S., Schwartz, E. D.: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A reviewCancer Res., 50, 3473 (1990).
Aso, T., Umeda, T., Nijima, T.: Alpha interferon therapy for renal cell carcinoma: Summary of four collaborative trials. In: Murphy, G. P., Khoury, S. (eds): Therapeutic Progress in Urological Cancers. Liss, New York 1989.
Horoszewicz, J., Murphy, G. P.: An assessment of current use of human interferons in therapy of urologic cancer.J. Urol., 142, 1173 (1989).
Edmonson, J. H., Kovach, J. S., Buckner, J. C., Kvols, L. K., Hahn, R. G.: Phase I study of difluoromethylornithine in combination with recombinant alpha 2a-interferon.Cancer Res., 48, 6584 (1988).
Schornagel, J. H., Verwejl, J., Hulnink, W. W. B., Klijn, J. G. H., Mulder, P. H. M., Debruyne, F. M. J., van Deijk, W. A., Roozendaal, K., Kook, T. C., Veenhof, K. H. N., Berkel, J., Van Oosterom, A. T.: Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.J. Urol., 142, 253 (1989).
Sella, A., Logothetis, C. J., Fitz, K., Dexeus, F. H., Amato, R., Kilborn, R., Wallace, S.: Phase II study of interferon-alpha and chemotherapy (5-fluoracil and mitomycin C) in metastatic renal cell cancer.J. Urol., 147, 573 (1992).
Beksac, M., Kansu, E., Kars, A., Ibrahimoglu, Z., Firat, D.: A rapid drug sensitivity assay for neoplastic cells.Med. Oncol. & Tumor Pharmacother. 5, 253 (1988).
Hanauske, A. R., von Hoff, D. D.: Clinical correlations with the human tumor cloning assay.Cancer Invest., 3, 541 (1989).
Lieber, M. M.: Soft agar colony formation assay for in-vitro chemotherapy sensitivity testing of human renal cell carcinoma.J. Urol., 131, 391 (1984).
Von Hoff, D. D.: In vitro predictive testing.Int. J. Cell Cloning, 5, 179 (1987).
de Riese, W., Allhoff, E., Stief, C. G., Lenis, G., Schlick, R., Liedke, S., Anton, P., Jonas, U.: In vitro sensitivity testing of human renal cell carcinoma with cytostatic agents and inferferon alpha-2a.Urol. Res., 19, 87 (1991).
Mickisch, G., Fajta, S., Kellhauer, G., Schlick, E., Tschada, R., Alken, P.: Chemosensitivity testing of primary human renal cell carcinoma by tetrazolium based microculture assay (MTT).Urol. Res., 18, 131 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Küpeli, S., Beksac, M., Küpeli, B. et al. Determination ofin vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma. International Urology and Nephrology 29, 421–426 (1997). https://doi.org/10.1007/BF02551107
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02551107